Cancer Drugs Will Continue To Command High Prices, Scully Predicts
Executive Summary
The transformation in the Medicare market will not prevent cancer drugs from commanding very high prices, former Centers for Medicare & Medicaid Services Administrator Tom Scully predicted during the Washington Research Group's annual symposium Nov. 5
You may also be interested in...
Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada
Targeted Oncologics Will Sustain High Prices With Clear Benefits, GSK Says
The high price tags of targeted therapies will continue to be supported as specific populations are identified where the oncologics can show a clear benefit, according to GlaxoSmithKline Chairman of R&D Tachi Yamada
Rx Industry Must Change “Mission” To Prepare For Medicare – Scully
The Medicare prescription drug benefit that begins in 2006 will fundamentally change the mission of pharmaceutical companies, former Centers for Medicare & Medicaid Services Administrator Tom Scully told the Washington Research Group's annual symposium in Washington, D.C. Nov. 5